Insider Transactions in Q2 2021 at Bei Gene, Ltd. (BGNE)
Insider Transaction List (Q2 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 29
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-42.21%
|
$528,000
$352.18 P/Share
|
|
Jun 29
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
Jun 28
2021
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
446
-100.0%
|
$162,790
$365.0 P/Share
|
|
Jun 28
2021
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
455
-100.0%
|
$164,710
$362.48 P/Share
|
|
Jun 28
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
425
-100.0%
|
$155,125
$365.0 P/Share
|
|
Jun 18
2021
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
486
-100.0%
|
$157,950
$325.89 P/Share
|
|
Jun 18
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
469
-100.0%
|
$152,425
$325.66 P/Share
|
|
Jun 18
2021
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
802
-100.0%
|
$265,462
$331.15 P/Share
|
|
Jun 18
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
1,156
-100.0%
|
$381,480
$330.93 P/Share
|
|
Jun 16
2021
|
Qingqing Yi Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+50.0%
|
-
|
|
Jun 16
2021
|
Jingshyh S Su Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+50.0%
|
-
|
|
Jun 16
2021
|
Corazon (Corsee) D. Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+50.0%
|
-
|
|
Jun 16
2021
|
Thomas Malley Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+31.35%
|
-
|
|
Jun 16
2021
|
Anthony C Hooper Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+50.0%
|
-
|
|
Jun 16
2021
|
Donald W. Glazer Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+0.28%
|
-
|
|
Jun 16
2021
|
Timothy Yung Cheng Chen Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,800
+50.0%
|
-
|
|
Jun 16
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
25,350
+7.69%
|
-
|
|
Jun 16
2021
|
Lai Wang Global Head of R&D |
BUY
Grant, award, or other acquisition
|
Direct |
53,625
+18.35%
|
-
|
|
Jun 16
2021
|
Xiaobin Wu President, COO & GM China |
BUY
Grant, award, or other acquisition
|
Direct |
78,000
+6.04%
|
-
|
|
Jun 16
2021
|
Xiaodong Wang Director |
BUY
Grant, award, or other acquisition
|
Direct |
39,000
+0.67%
|
-
|
|
Jun 16
2021
|
John Oyler Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
146,250
+2.06%
|
-
|
|
Jun 16
2021
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
31,200
+31.33%
|
-
|
|
Jun 10
2021
|
Timothy Yung Cheng Chen Director |
SELL
Open market or private sale
|
Direct |
2,836
-57.29%
|
$998,272
$352.07 P/Share
|
|
Jun 10
2021
|
Timothy Yung Cheng Chen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,836
+50.0%
|
$87,916
$31.59 P/Share
|
|
Jun 09
2021
|
Timothy Yung Cheng Chen Director |
SELL
Open market or private sale
|
Direct |
3,164
-69.92%
|
$1,110,564
$351.62 P/Share
|
|
Jun 09
2021
|
Timothy Yung Cheng Chen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,164
+50.0%
|
$98,084
$31.59 P/Share
|
|
Jun 07
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
603
-100.0%
|
$211,653
$351.55 P/Share
|
|
Jun 07
2021
|
Lai Wang Global Head of R&D |
SELL
Open market or private sale
|
Direct |
656
-100.0%
|
$232,224
$354.26 P/Share
|
|
Jun 07
2021
|
Howard Liang CFO & Chief Strategy Officer |
SELL
Open market or private sale
|
Direct |
650
-100.0%
|
$230,100
$354.16 P/Share
|
|
Jun 07
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
3,398
-94.26%
|
$1,196,096
$352.48 P/Share
|
|
Jun 03
2021
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
7,400
-0.27%
|
-
|
|
Jun 01
2021
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
69,000
-2.44%
|
-
|
|
Jun 01
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
540
-100.0%
|
$195,480
$362.64 P/Share
|
|
May 31
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
540
+50.0%
|
-
|
|
May 31
2021
|
Jane Huang CMO, Hematology |
BUY
Grant, award, or other acquisition
|
Direct |
7,189
+2.4%
|
-
|
|
May 28
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-49.01%
|
$534,000
$356.55 P/Share
|
|
May 28
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|
|
May 27
2021
|
Donald W. Glazer Director |
SELL
Bona fide gift
|
Direct |
4,700
-0.17%
|
-
|
|
May 10
2021
|
Xiaodong Wang Director |
SELL
Open market or private sale
|
Direct |
3,394
-61.58%
|
$1,021,594
$301.23 P/Share
|
|
May 10
2021
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,394
+50.0%
|
$0
$0.13 P/Share
|
|
May 10
2021
|
Xiaodong Wang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
44,109
+0.76%
|
$0
$0.13 P/Share
|
|
May 03
2021
|
Xiaobin Wu President, COO & GM China |
SELL
Open market or private sale
|
Direct |
6,715
-100.0%
|
$2,303,245
$343.0 P/Share
|
|
Apr 29
2021
|
Jane Huang CMO, Hematology |
SELL
Open market or private sale
|
Direct |
1,500
-41.73%
|
$531,000
$354.48 P/Share
|
|
Apr 29
2021
|
Jane Huang CMO, Hematology |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+50.0%
|
$43,500
$29.49 P/Share
|